Incyte reported preliminary data showing its experimental agent targeting calreticulin‑mutant myelofibrosis produced meaningful spleen responses and symptom improvements in patients with advanced disease, according to ASH presentations. Company analysts framed the data as evidence the drug could be a new approach for a disease where existing JAK inhibitor options are limited. The program arrives as Incyte faces patent cliffs for its JAK inhibitor franchise and needs novel agents to sustain growth. Observers said the next steps will focus on durability, safety in broader populations, and head‑to‑head positioning versus established therapies like ruxolitinib.